Showing results (301-310 of 758) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|January 19, 2019
Factors affecting adenoma detection rate in a national flexible sigmoidoscopy screening programme: a retrospective analysisRoisin Bevan, Roger G Blanks, Claire Nickerson, et al.
The Lancet. Gastroenterology & Hepatology|December 7, 2019
Current and potential treatments for primary biliary cholangitisRaj A Shah, Kris V Kowdley
The Lancet. Gastroenterology & Hepatology|November 1, 2019
Modifiable pathways for colorectal cancer: a mendelian randomisation analysisAlex J Cornish, Philip J Law, Maria Timofeeva, et al.
The Lancet. Gastroenterology & Hepatology|November 15, 2020
The overlap between irritable bowel syndrome and organic gastrointestinal diseasesImran Aziz, Magnus Simrén
The Lancet. Gastroenterology & Hepatology|February 24, 2018
Post-imaging colorectal cancer or interval cancer rates after CT colonography: a systematic review and meta-analysisAnu E Obaro, Andrew A Plumb, Thomas R Fanshawe, et al.
The Lancet. Gastroenterology & Hepatology|October 29, 2021
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trialSylke Haal, Maimoena S S Guman, Thomas C C Boerlage, et al.
The Lancet. Gastroenterology & Hepatology|April 30, 2022
Nationwide hepatitis C virus screening and treatment of adolescents in Egyptian schoolsEhab Kamal, Noha Asem, Mohamed Hassany, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Shortening the duration of therapy for chronic hepatitis C infectionBenjamin Emmanuel, Eleanor M Wilson, Thomas R O'Brien, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2017
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Victor Pântea, Valentin Cebotarescu, et al.
Pageof 76